Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9331502 | 0.76 | DRD3 (0.44) | KDM1AMAPTMEN1KMT2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL9331483 | 0.76 | DRD3 (0.44) | KDM1ABCHEMAPTMEN1KMT2A | |
| SCHEMBL8973036 | 0.74 | BCHE (0.41) | KDM1ABCHEMAPTGAAALDH1A1 | |
| SCHEMBL9331583 | 0.72 | LMNA (0.37) | KDM1ABCHEMAPTMEN1KMT2A | |
| SCHEMBL9332058 | 0.72 | HDAC3 (0.45) | BCHEMAPTMEN1KMT2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL9332079 | 0.72 | HRH1 (0.43) | BCHEMAPTMEN1KMT2ASLC6A2 | |
| SCHEMBL9759044 | 0.71 | LMNA (0.42) | KDM1AMAOABCHEMAPTSLC6A2 | |
| SCHEMBL6556075 | 0.70 | SLC6A4 (0.36) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL9759278 | 0.70 | USP2 (0.34) | KDM1ABCHEMAPTPTGS1PTGS2 | |
| SCHEMBL12386881 | 0.70 | PTGS1 (0.51) | MAOABCHEMAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130204238-A1 | COMBINATION THERAPY | FOLLICA, INC (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2552323-A1 | COMBINATION THERAPY | Follica, Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| US-8252749-B2 | Methods, kits, and compositions for generating new hair follicles and growing hair | FOLLICA, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120156228-A1 | Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair | FOLLICA, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012067630-A1 | HAIR GROWTH TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012067631-A1 | BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012067632-A1 | SEQUENTIAL BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| WO-2011123218-A1 | COMBINATION THERAPY | FOLLICA, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0100033-B1 | SUBSTITUTED (10H-PHENOTHIAZIN-10-YL)PROPYL-1-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEREAPEUTIC AGENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-01-14 | — | — | EP | disclosed |
| EP-0100033-B1 | SUBSTITUTED (10H-PHENOTHIAZIN-10-YL)PROPYL-1-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEREAPEUTIC AGENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-01-14 | — | — | EP | disclosed |
| US-4471116-A | Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines | HOFFMANN-LA ROCHE INC. (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0100033-A1 | Substituted (10H-phenothiazin-10-yl)propyl-1-piperazine derivatives, process for their preparation and thereapeutic agents containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-08 | — | — | EP | disclosed |
| EP-0100033-A1 | Substituted (10H-phenothiazin-10-yl)propyl-1-piperazine derivatives, process for their preparation and thereapeutic agents containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-08 | — | — | EP | disclosed |
| EP-0100033-A1 | Substituted (10H-phenothiazin-10-yl)propyl-1-piperazine derivatives, process for their preparation and thereapeutic agents containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | KDM1A 4496/4885MAOA 1263/4885BCHE 392/4885 |
| US-20120156228-A1 | Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair | NGF, HDGF, SHH | KDM1A 2646/4885MAOA 1168/4885BCHE 2980/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | KDM1A 3260/4885MAOA 1359/4885BCHE 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.